Chukwuemeka Ikpeazu

Associate Professor

University of Miami Miller School of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (1)

Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described in single-institution studies but not in randomized studies. EA3163 was a randomized study investigating whether cytoreductive neoadjuvant chemotherapy would improve SP or overall survival (OS). Patients and Methods: Patients with T3/T4a and select T4b NPNSCC requiring orbital or base of skull (BOS) resection were randomized to surgery (arm A) versus surgery preceded by docetaxel/cisplatin for three cycles (arm B). The degree of anticipated SP (orbit and BOS) was required preoperatively and after chemotherapy. SP was noted at surgery. Co-primary objectives were the SP rate (orbit/BOS) and OS. Eighty-two patients needed to be accrued for 81% power with a 0.1 one-sided alpha using Fisher’s exact test for SP rate and 83% with a 0.1 one-sided alpha using the log-rank test for OS. Results: Among 23 evaluable patients, the overall SP rate was 30%: 15% in arm A ( N = 2/13; 95% confidence interval (CI), 1.9%–45.4%) and 50% in arm B ( N = 5/10; 95% CI, 18.7%–81.3%; P = 0.17). Among 18 patients with pathologic T3/T4a disease, the overall SP rate was 39%: 18% in arm A ( N = 2/11; 95% CI, 2.3%–51.8%) and 71% in arm B ( N = 5/7; 95% CI, 29.0%–96.3%; P = 0.049). Orbit and BOS-specific preservation rates were 38% (95% CI, 8.5%–75.5%) versus 83% (95% CI, 35.9%–99.6%) and 33% (95% CI, 9.9%–65.1%) versus 67% (95% CI, 29.9%–92.5%) in arm A versus B, respectively. The most common grade ≥3 toxicities included mucositis, anemia, nausea and lymphopenia (all >10%). No grade 5 events were reported. Conclusions: These results support neoadjuvant chemotherapy as an effective intervention for SP in T3/T4a NPNSCC and deserve further evaluation.

Year:

2025

Collaborators (11)

Fenghai Duan

Professor

Brown University

UNITED STATES
View details

Christopher Le

Professor

University of Arizona College of Medicine

UNITED STATES
View details

Nabil F. Saba

-

UNITED STATES
View details

Peter H. Hwang

-

UNITED STATES
View details

Rathan M. Subramaniam

Duke University

UNITED STATES
View details

Rita Axelrod

Professor

Thomas Jefferson University

UNITED STATES
View details

Ehab Y. Hanna

-

UNITED STATES
View details

Barbara Burtness

Professor

Yale University School of Medicine

UNITED STATES
View details

Paul Swiecicki

University of Michigan

UNITED STATES
View details

Carl Snyderman

Professor

University of Pittsburgh

UNITED STATES
View details

Dong M. Shin

Professor

Emory University

UNITED STATES
View details